Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeyondSpring Inc.    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.

Number of employees : 61 people.
Managers
NameAgeSinceTitle
Lan Huang, Dr.492014Chairman & Chief Executive Officer
Richard J. Daly582018Chief Operating Officer
Elizabeth Adkins Czerepak632020Chief Financial Officer
Ramon W. Mohanlal, Dr.602020Director & Chief Medical Officer
James Tonra, Dr.-2020Chief Scientific Officer
Matthew Kirkby-2016Independent Director
Quan Qi Song, Dr.542016Independent Director
Yanbin Xie, Dr.612016Director
Christine Ying Zhao472016Independent Director
Patrick Fabbio512018Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 30,117,881 3,613,983 12.0% 0 0.0% 12.0%
Shareholders
NameEquities%
Lan Huang 10,367,037 34.4%
Decheng Capital LLC 3,458,142 11.5%
Mulong Liu 2,105,494 6.99%
Quan Qi Song 689,759 2.29%
HBM Partners AG (Investment Management) 285,130 0.95%
Ramon W. Mohanlal 220,098 0.73%
SSgA Funds Management, Inc. 216,606 0.72%
Northern Trust Investments, Inc.(Investment Management) 167,870 0.56%
BlackRock Fund Advisors 166,707 0.55%
Shanghai Fosun Industry Investment Co., Ltd. 155,564 0.52%
Company contact information
BeyondSpring, Inc.
28 Liberty Street
39th floor
New York, NY 10005

Phone : +1.646.305.6387
Fax : +1.646.882.4228
Web : http://www.beyondspringpharma.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
BEYONDSPRING INC.-4.32%447
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097
GENMAB A/S49.17%22 988
BIONTECH SE161.78%21 124
HUALAN BIOLOGICAL ENGINEERING INC.89.62%13 988
MYOKARDIA, INC.205.92%11 889
ARGENX SE45.54%11 712
SAREPTA THERAPEUTICS, INC.6.73%10 813
NEUROCRINE BIOSCIENCES, INC.-7.89%9 233
ASCENDIS PHARMA A/S14.83%8 499
MIRATI THERAPEUTICS, INC.39.84%8 026
EXELIXIS, INC.26.50%6 888
BIOCON LIMITED42.05%6 698
ACCELERON PHARMA INC.106.22%6 549
ARROWHEAD PHARMACEUTICALS, INC.-7.17%6 023
PEPTIDREAM INC.-13.30%5 825
ULTRAGENYX PHARMACEUTICAL INC.117.89%5 638